Healthcare Sector Theme: Defensive Positioning in Uncertain Times

The Macro Backdrop

May 2026 presents a complex landscape for healthcare investors. tariff escalations, inflationary pressures, and Fed policy uncertainty have driven a clear risk-off rotation across equity markets. Within this environment, healthcare's traditional defensive characteristics are drawing renewed institutional interest.

Why Healthcare Defends

The sector's defensive reputation rests on several structural pillars:

Non-discretionary demand: Pharmaceuticals and medical services exhibit low elasticity regardless of economic conditions

Pricing power: Large pharmaceutical companies can pass through inflation via portfolio diversification and patent protection

Capital return: Sector leaders maintain robust dividend programs and share buyback schedules

Correlation characteristics: Healthcare has historically demonstrated lower beta to broad market selloffs

Scoring Update: Defensive Leaders

Ticker	Score	Thesis
--------	-------	--------
LLY	73	GLP-1 momentum continues; portfolio depth supports multiple expansion
UNH	62	Defensive enrollment growth; cost management improves margins
MRK	65	Keytruda franchise stability; pipeline optionality underappreciated
ABBV	58	Immunology diversification; M&A speculation adds premium potential
JNJ	50	Legal overhang persists; asset sales and capital return provide support
ABT	55	Medtech stability; diagnostic division offers positive surprise potential
PFE	45	Pipeline concerns mount; yield and restructuring narrative limited
TMO	54	Quality franchise but limited near-term catalyst

Key Risks to Monitor

1. Policy exposure: Drug pricing legislation remains a tail risk for large pharma 2. GLP-1 competition: Novo Nordisk and other entrants creating binary dynamics for leaders 3. Medtech tariff sensitivity: Supply chain concentration warrants monitoring 4. Credit cycle correlation: If economic deterioration accelerates, even defensive sectors face multiple compression

Positioning Strategy

For the current environment, the framework prioritizes:

1. Quality over value: Balance sheet strength and cash generation more important than cheap valuations 2. Growth at reasonable price: GLP-1 beneficiaries warrant premium multiples if growth remains intact 3. Diversification: Single-stock exposure to patent cliff risks requires portfolio-level hedging